preventing relapse
DESCRIPTION
PREVENTING RELAPSE. Lee B. Reichman, MD, MPH Northeast TB Controllers Meeting October 24, 2006 Princeton, New Jersey. Reported TB Cases United States, 1982 – 2005. No. of Cases. 1982. 1987. 1991. 1995. 1999. 2005. Year. Trends in Tuberculosis – United States, 2005. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/1.jpg)
![Page 2: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/2.jpg)
PREVENTING RELAPSEPREVENTING RELAPSE
Lee B. Reichman, MD, MPH
Northeast TB Controllers Meeting
October 24, 2006
Princeton, New Jersey
![Page 3: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/3.jpg)
Reported TB Cases United States, 1982–2005
Reported TB Cases United States, 1982–2005
10,000
15,000
20,000
25,000
Year
1982 1987 1991 1995 1999 2005
No
. of
Ca
ses
![Page 4: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/4.jpg)
Trends in Tuberculosis – United States, 2005
Trends in Tuberculosis – United States, 2005
• Deceleration of the decline in the overall national TB rate, the persistent disparities in TB rates between U.S.-born and foreign-born persons and between whites and racial/ethnic minorities, and the increase in MDR TB cases all threaten progress toward the goal of TB elimination in the United States
• Effective TB control and prevention in the United States require sufficient resources, continued collaborative measures with other countries to reduce TB globally, and interventions targeted to U.S. populations with the highest TB rates
![Page 5: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/5.jpg)
The U-Shaped Curve of ConcernThe U-Shaped Curve of Concern
![Page 6: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/6.jpg)
Tuberculosis: No Longer a Problem?
Tuberculosis: No Longer a Problem?
CDC TB Related News Items Weekly Update6 month sample: October 1, 2003 - March 31, 2004
• 117 articles from 33 states on all aspects of TB
• 76 reports of TB outbreaks: (almost 1 every 2-3 days)– Schools and colleges 38– Prisons 8– Hospital/Nursing Home 7– Workplace 16– Homeless 7
- J. Seggerson, NCET WIRE, April 2004
![Page 7: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/7.jpg)
Federal News RadioFederal News Radio
![Page 8: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/8.jpg)
CNNCNN
![Page 9: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/9.jpg)
NBC 4NBC 4
![Page 10: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/10.jpg)
ResultsResults
![Page 11: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/11.jpg)
TB OnboardTB Onboard
![Page 12: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/12.jpg)
XDRTBXDRTB
• 1539 Patients with Isolates sent
• 544 Culture-Positive for M.Tb– 35% of total
• 221 Resistant to Isoniazid & Rifampin (MDR TB)– 40% of M.Tb and 14% of total
• 53 Resistant to all tested drugs (XDR TB)– 24% of MDR TB, 10% MTB and 3% of total
-G. Friedland, Int Conf on AIDS, 2006
![Page 13: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/13.jpg)
XDRTB PatientsPrior TB Treatment or Hospitalization
XDRTB PatientsPrior TB Treatment or Hospitalization
Characteristics XDR TB Patients n (%)
Prior TB Treatment:
No prior TB treatment 26 (51%)
Cure or completed treatment 14 (28%)
Default or Treatment Failure 7 (14%)
Prior Hospitalization: 32 (64%)
-G. Friedland, Int Conf on AIDS, 2006
![Page 14: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/14.jpg)
XDRTB MortalityXDRTB Mortality
• 52 of 53 (98%) of XDR patients have died
• Median survival from date sputum collected was 16 days (IQR 2-210 days)
– No significant difference by HIV status, previous or use of ARVs
-G. Friedland, Int Conf on AIDS, 2006
![Page 15: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/15.jpg)
The New York TimesSeptember 14, 2006
The New York TimesSeptember 14, 2006
EDITORIAL: Extreme TuberculosisMore funding is needed to catch up with new, extensivelydrug-resistant strains of tuberculosis.
![Page 16: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/16.jpg)
Patient Involvement in Medical Care Patient Involvement in Medical Care
• Patients and their families have become increasingly involved—and influential—in all aspects of medical care
• In the mid-eighties, as the first anti-viral drugs for treating AIDS were being developed, activists demanded to participate in the design of clinical trials directed by the National Institutes of Health and pharmaceutical companies
• Inspired by the activists’ example, breast cancer patient-advocacy groups made similar requests
• The AIDS groups interrupted meetings and staged “die-ins” at the N.I.H.
• Eventually, the physicians in charge of planning the clinical trials agreed to their demands
• Laypeople now routinely sit on committees on the N.I.H. and on hospitals’ institutional review boards, which assess the ethicality and scientific merit of clinical trials
![Page 17: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/17.jpg)
The Patient’s Charter for Tuberculosis Care
The Patient’s Charter for Tuberculosis Care
![Page 18: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/18.jpg)
The Patient’s Charter for Tuberculosis Care
The Patient’s Charter for Tuberculosis Care
• Initiated and developed by patients from around the world
• Outlines rights and responsibilities of people with tuberculosis
• Sets out the ways in which patients, the community, health providers (both private and public), and governments can work as partners in a positive and open relationship
• Practices principle of Greater Involvement of People with Tuberculosis
• Affirms that empowerment is catalyst for effective collaboration with health providers and authorities
![Page 19: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/19.jpg)
Patient’s RightsPatient’s Rights
You have the right to:
Care;
Dignity;
Information;
Choice;
Confidence;
Justice;
Organization;
Security
![Page 20: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/20.jpg)
Patient’s ResponsibilitiesPatient’s Responsibilities
You have the responsibility to:
Share information;
Follow treatment;
Contribute to Community Health
Show Solidarity
![Page 21: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/21.jpg)
Deaths Due To:Deaths Due To:
TB (annually)
2 - 3,000,000
SARS
813
Angola Marburg Hemorrhagic Fever
329
Avian Influenza
144
Anthrax
5
Mad Cow Disease
1 (Cow)
Smallpox
0
![Page 22: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/22.jpg)
Reichman’s Prediction Reichman’s Prediction • The continued rise of the TB in the world and the leveling off of
tuberculosis in the US portends a significant global resurgence of TB followed by a frightening resurgence of MDRTB still diagnosed and treated with old tools
• The resurgence will continue unabated followed by subsequent transmission to healthcare workers and through that vector to the community at large
• Subsequent global re-establishment of control of tuberculosis will then entail more staggering costs, both in cash and hysteria than has ever been contemplated
• New drugs and New Diagnostics and an effective vaccine will enhance the TB community’s success in turning this around which once again will depend on energizing others to make our case
![Page 23: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/23.jpg)
![Page 24: PREVENTING RELAPSE](https://reader033.vdocuments.site/reader033/viewer/2022061511/56814976550346895db6c415/html5/thumbnails/24.jpg)
INFORMATION LINE1•800•4TB•DOCS (482-
3627)www.umdnj.edu/globaltb